XXXX : surgical management and clinical outcome.

@entity43 @entity1 @entity41 @entity5 @entity1442
OBJECTIVES: The objectives of this study were to characterize the prognostic features of @entity43 ( @entity43 ), examine the clinical impact of surgical staging, and define the role of cytoreductive surgery for @entity1 with @entity1442 . METHODS: Fifty-one @entity1 with @entity43 were identified from hospital and @entity5 registry databases. Demographic, operative, pathologic, and follow-up data were abstracted retrospectively. Survival curves were generated using the Kaplan-Meier method, and statistical comparisons were performed using the log rank test, logistic regression analysis, and the Cox proportional hazards regression model. RESULTS: The median age at diagnosis was 45 years, and follow-up extended to a median of 43.0 months. Stage I/II disease was present in 25.5% of @entity1 and no disease-related deaths were observed in this group. @entity5 was discovered in 29.4% of @entity1 with @entity5 clinically confined to the ovaries. Stage III/IV disease (74.5% of cases) was associated with median progression-free and overall survival times of 32.8 and 114.2 months, respectively. Menopausal status and the anatomic extent of disease were significantly associated with survival outcome. However, the strongest independent predictor of survival for @entity1 with @entity1442 was the amount of @entity41 . Median overall survival for @entity1 with optimal cytoreduction (residual disease </=1 cm) was 115.4 months compared to 43.1 months for those with >1 cm @entity41 (P < 0.0002). CONCLUSIONS: @entity43 carries a significant risk of extraovarian spread; however, adequately sampled Stage I/II disease is associated with a favorable prognosis. Optimal cytoreduction is associated with improved survival and should be the primary therapeutic objective for @entity1 with advanced-stage @entity43 .
